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Abstract 
 
MITOCHONDRIAL GENE EXPRESSION IN HUMAN 
MONONUCLEAR CELLS 
 
By Monika D. Ruchała, M.S. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2014. 
 
Director: Dr. James P. Bennett Jr, M.D., Ph.D., Bemiss Professor 
Departments of Neurology, Psychiatry and Physiology and Biophysics 
 
Adult neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), have 
been intensively studied in recent years in pursuit of mechanisms responsible for origin 
and progression. One emerging theme is mitochondrial energetic deficiency as a 
mechanism of neuronal death. Recent descriptions of protocols to generate induced 
pluripotent stems cells (iPSCs) from living patients offer the potential to create unique 
disease models. This model can potentially lead to crucial advances in developing 
treatment options for a wide variety of neurodegenerative diseases. In this thesis, we 
attempt to induce iPSCs from mononuclear cells (MNC) in peripheral blood acquired 
from patients with ALS and healthy control (CTL) subjects, and analyze their 
mitochondrial genomes. The reprogramming of MNC to yield iPSC was done by 
nucleofection of an episomal plasmid pEB- C5, expressing OriP sequences of the 
Epstein­Barr and five reprogramming transgenes Oct4, Sox2, Klf4, c-Myc and Lin28. We 
investigated the expression of mitochondrial DNA genes, ND2, ND4, COXIII and 12s 
rRNA in the ALS and CTL MNC before and after their culturing. The results implicate 
deregulated mitochondrial bioenergetics as a characteristic of ALS. Future work will 
   
 
establish whether these abnormalities in mitochondrial bioenergetics persist in iPSC’s 
and iPSC-derived neurons from ALS subject
   
 1 
Chapter 1: 
1.1 Amyotrophic Lateral Sclerosis (ALS)  
Neurodegeneration is a debilitating process in which nerve cells slowly lose their 
functionality and/or die over many years, producing clinical manifestations of 
neurodegenerative diseases. These widespread diseases of the nervous system affect 
humans in different ways and produce symptoms both within the brain and in different 
somatic tissues, impeding their proper functioning. Common neurodegenerative diseases 
include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Amyotrophic 
lateral sclerosis (ALS). The origins of these diseases are thought to be multi-factorial, 
genetic, as well as environmental. 
 
Jean Martin Charcot first described “Lou Gehrig’s Disease,” the eponym created in the 
US in honor of a Yankee baseball player diagnosed with ALS at age 39, in 1869 as a 
motor neuron disease (Charcot and Joffroy, 1869). He observed an abnormal appearance 
of white matter and reactive astrocytes and microglia in lateral corticospinal tracks. This 
myelin pallor (pallere -be pale in Latin, lack of color and sickliness) and gliosis (reactive 
response to damage) indicated degeneration of axons of upper motor neurons descending 
from the brain’s precentral gyrus (primary motor cortex) to the spinal cord. Originally 
named Charcot’s sclerosis, the disease was eventually named amyotrophic lateral 
sclerosis as the axonopathy of the upper motor neurons was associated with degeneration 
of lower motor neurons in the spinal cord and manifested in the atrophy of muscles 
(Boillee et al., 2006; Nelson, 2003). In Europe, ALS is called motor neuron disease, 
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which unambiguously conveys an explanation of the source of muscle weakness that is 
motor neuron degeneration (Nelson, 2003). 
 
The lifetime risk for ALS has been estimated as 1 in 1000, with 1-2 per 100000 of new 
cases per year and 4-6 per 100000 of affected individuals (Boillee et al., 2006). That 
translates, according to the ALS Association, to approximately 5,600 people in the U.S. 
diagnosed with ALS each year, and 30,000 Americans having the disease at any given 
time. Typically the disease affects middle-aged people (40-60 years old) but it can also 
strike at the younger age. Currently, there is no cure for ALS. It has been reported that 
50% of the deaths occur within three years from the disease onset (Saris et al., 2009; 
Dupuis et al., 2011; Boillee et al., 2006). The most common form of ALS is sporadic, 
which have been thought to account for 90% of all ALS cases (Saris et al., 2009; Dupuis 
et al., 2011;Boillee et al, 2006). However, a recent Medline literature review and meta 
analysis of previously reported data, indicated that the familial form of ALS accounts for 
only 5.1 % (not 10 %) of all ALS cases, with even lower rate in Southern Europe. This 
discrepancy have been attributed to the fact there was a preferential recruitment of 
familial ALS patients, and that there is no clear definition of relatedness with only two 
members of extended family to be considered related (Byrne et al., 2014). Most ALS 
cases thus occur sporadically ~95% of the time. 
 
The first manifestation of ALS differs between individuals. Some patients experience 
muscle weakness and cramping in hands, arms or legs. Others have difficulty speaking 
and projecting their voice as a result of facial muscle weakness. The disease progresses to 
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speech impairment and spasticity, and at more advanced stages to muscle atrophy, 
shortness of breath and consequently to paralysis of respiratory muscles and death. ALS 
not only affects the nervous system but also other body tissues as shown by genome wide 
studies of sporadic ALS (Dupuis et al., 2011).  
 
As a consequence of the multivariate onset and presentation of ALS, it is sometimes 
called a syndrome rather than the nosological disease entity. The multifaceted and 
versatile presentation of ALS challenges its diagnosis. Clinicians perform meticulous 
neurological examinations and tests to exclude other neurological diseases, rather than 
identify ALS by looking solely at its symptoms. Some of these tests include 
electromyography (EMG), nerve conduction velocity (NCV), high-resolution serum 
protein electrophoresis, lumbar puncture, myelograms (now MRI scans) of cervical spine 
and muscle and/or nerve biopsy.  
Mutations in many different genes are associated with Familial ALS (FALS)  
Studies of familial forms of ALS (FALS) indicate that this autosomally dominant disease 
is associated with the mutations of genes located on at least six different chromosomes. 
Mutations leading to typical ALS, with a late-onset, progressive deterioration of upper 
and lower motor neurons are located on chromosomes 21, 18, 16, and 20 at the loci called 
ALS1, ALS3, ALS6 and ALS7 respectively.  
 
The only gene identified for the clinically typical ALS is the one that encodes 
Copper/Zinc Super Oxide Dismutase (Cu/Zn SOD1), which converts (“dismutates”) 
superoxide to hydrogen peroxide and is localized mainly to cytosol. It is located on 
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chromosome 21 at the locus ALS1 (Dupuis et al. 2011; Boillee et al. 2006; Nelson, 
2003).  
 
Out of two forms of ALS with dementia, frontal temporal dementia (FTD) and FTD with 
Parkinson’s disease (FTDPD), only the locus called ALS-FTD has been successfully 
related to a gene (MAPT), which is a microtubule-associated protein. This locus is 
located on chromosome 17 and ALS-FTD locus is located on chromosome 9. An 
atypical, heterogeneous form of ALS, manifested by unusual tremor, is caused by a 
mutation in vesicle associated membrane protein B (VAMB) gene that is located on 
chromosome 20 at the locus called ALS8. The gene product is involved in a vesicular 
transport from endoplasmic reticulum to Golgi apparatus and transport of cargo to 
membrane in an axon. Another atypical form of ALS related to a mutation on 
chromosome 2 at the locus associated with progressive lower motor neuron disease. The 
gene found at this locus, DCTN1, codes for a dydactin subunit, which is a part of axonal 
transport. The onset of this form of ALS is observed in adults and leads to vocal-cord 
paralysis.  
 
The names of the loci ALS2, ALS4, and ALS5 located on chromosomes 2, 9 and 15 
respectively, are in some way misnomers because those mutations are associated with 
juvenile forms of motor neuron diseases, not ALS (Rosen et al., 1993; Hand et al., 2002; 
Chen et al., 2004; Hadano et al., 2001; Nishimura et al., 2004; Boillee et al., 2006). 
Numbers of studies have also identified genes that promote ALS progression. According 
to gene analysis of human postmortem sensory and motor cortexes, ALS subjects showed 
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differential expressions of 275 genes (Wang et al., 2006). Ten of those genes were 
upregulated; six associated with surface activity and two with glutamate receptors 
(consistent with excitoxicity of glutamate). The remaining, down-regulated more than 
four fold genes were: zinc finger protein 36, C3H type-like 1, inhibitor of DNA binding 
4, and heterogeneous nuclear ribonucleoprotein H1 (group of genes were involved in 
transcription), ribosomal protein S11, (protein/amino acid synthesis and turnover group) 
nuclear receptor subfamily 4, group A, member 3, and inhibin, beta C 
(neurotransmission, hormones group), vascular endothelial growth factor (survival and 
growth), small protein effector 1 of Cdc42 (signaling), dynein 2 light intermediate chain 
(cytoskeletal tubulin and cell adhesion molecule), transducer of ERBB2, 1 
(differentiation or proliferation ), protein regulated in glioma and forming binding protein 
3 (growth factor receptor-bound protein) (Wang et al., 2006).   
 
A decrease in vascular endothelial growth factor (VEGF) as a consequence of a mutation 
in a promoter region of VEGF gene has been linked to increased risk of ALS in Belgium, 
Sweden, and Britain (Lambrechts et al., 2003; Gros-Louis et al., 2003). This growth 
factor is essential in angiogenesis not only the developmental, but also hypoxia-induced 
(Wang, 2006.) Angiogenesis can be also negatively affected by a mutation in angenin 
gene ANG, mainly in the core subunit (Boillee et al., 2006; Greenway et al., 2006).  
 
Neurofilament’s mutations may be also a risk factor for ALS although there is no 
conclusive linkage between the disease and the NF aggregates observed in familial and 
sporadic ALS patients (Garcia et al., 2006). Other down-regulated genes were involved in 
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ubiquitin- proteasome function, apoptosis, lipid metabolism, inflammation, oxidative 
stress and energy metabolism. Specifically, down regulated genes related to 
mitochondrial energy metabolism included: methionine adenosyltransferase II alpha, 
myotubularin related protein, thioredoxin, and CD24 antigen (small cell lung carcinoma 
cluster 4 antigen) (Wang et al., 2006). 
 
Energy deregulation plays a central role in ALS progression. In a healthy person intake of 
energy in form of food and production of energy normally equilibrates energy 
expenditure. An overeating, static life style leads to insulin resistance, which results in a 
decreased energy delivered to cells as in diabetes mellitus type 2. On the other hand 
raised oxygen consumption, decreased food intake or mitochondrial dysfunction lead to 
weight loss and malnutrition. In ALS patients, for reasons currently unknown, the energy 
balance is interrupted by hypermetabolism, which precedes denervation. Studies of 
sporadic ALS of genes responsible for metabolism led to no conclusive results. What is 
also baffling is that ALS patients experience hyper lipidemia with increased LDL/HDL 
ratio (Dupouis et al., 2011).  
Does study of motorneuron groups help us understand their vulnerability in ALS? 
To understand selective vulnerability to degeneration of motor neurons in different areas 
of the nervous system in different neurodegenerative diseases, neurons of rats were 
isolated by laser capture microdissection and following areas were analyzed: 
oculomotor/trochlear (cranial nerve 3/4, unaffected in ALS), hypoglossal (cranial nerve 
12, affected in ALS) and lateral motor column of the cervical spinal cord (highly affected 
in ALS). Analyzed gene expression of these regions revealed that all regions exhibited 
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unique gene expression profiles; however, there was some similarity in CN12 and lateral 
spinal column gene expression. All of the regions had differential expression of Hox 
genes, mitochondrial functions, ubiquitination, apoptosis regulation, nitrogen 
metabolism, calcium regulation, transport, and RNA processing genes (Hedlung et al, 
2010). This is consistent with observations of aggregates caused by mutations in the 
genes of ubiquitin, TAR DNA binding protein of 43-kDa (TDP-43), and fused sarcoma 
protein (FUS) in ALS mouse models (Kwiatkowski et al., 2009; Dupuis et al., 2011). 
These studies did not reveal any selective properties of ALS-vulnerable neuron 
populations compared to those that typically do not degenerate in ALS. 
SOD1 mutations can cause Familial ALS (FALS) 
Out of all genetically inherited forms of ALS, it has been previously reported that 
mutation in SOD1 accounts for 10-20% of FALS cases (Boillee et al., 2006; Wang et al., 
2006). Specifically, mutation of alanine to valine-SODA4V elicits the most aggressive 
form of ALS and is the most prevalent one in the US (50%) (Boillee et al., 2006). 
However, according to the only population based study that was conveyed in Italy, the 
SOD1 mutation accounted for only 13.6% of FALS (Chio et al., 2008; Byrne et al., 
2014). 
The gene product of SOD1 gene is 153 amino acids long and it is mainly cytosolic, but 
some appears to be mitochondrial. Its function is to detoxify superoxide anion by 
converting it to hydrogen peroxide that is ultimately detoxified to water. It had been 
therefore postulated that the loss of this dismutase function might be associated with ALS 
phenotype. However this did not seem to be the case because in a course of different 
research undertakings, it was shown that active and inactive enzyme result in similar 
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disease presentation (Fischer et al., 2004; Frey et al., 2000; Pun et al., 2006) Moreover, 
the deletion of the enzyme in mice does not produce an ALS phenotype (Reaume et al., 
1996). SOD1 requires Cu and Zn for proper functioning. Copper, toxic if free in the cell, 
loaded into SOD1 aids the oxidative process. A study of mice with eliminated copper 
showed however no difference in ALS phenotype (Subramaniam et al., 2002; Boillee et 
al.2006; Wang et al., 2006).  On the other hand it has been shown in SOD1 mutant mice 
that zinc deficiency can accelerate the disease manifestation and in that situation 
mitochondrial SOD1 generates more free radicals (Wang et al., 2006).  
 In a search for an explanation of unknown source of toxicity of SOD1 mutation it 
has been proposed that it might be a result of a defective protein folding. This could 
explain aggregations of SOD1, which are one of the trademarks of ALS (Wang et al., 
2003). These SOD1 aggregates bind to many cellular components negatively affecting 
their function. Among some of them are proteasomes, in which SOD1 aggregate binding 
leads to abnormal protein degradation, and chaperones, which lead to impaired protein 
folding. Moreover, mutant SOD1 that is imported to mitochondria interrupts calcium 
buffering, electron transport chain, and protein import by blocking import machinery, and 
might be a cause of initiating apoptotic pathways by binding to and inactivating Bcl-2 
(Boillee et al., 2006). ALS also affects mitochondria structurally, based on observations 
of enlarged, disorganized mitochondrial membranes in motor neurons (Dupuis et al., 
2003).  
 Global gene expression profiling study of SOD1mutant overexpression in mice 
showed that the instigation of the disease relates to motor neurons, while advances of the 
disease are promoted by astrocytes and microglia (Hedlung et al., 2010). A healthy motor 
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neuron consists of up to ~one-meter-long axon, through which transport of cargo takes 
place. Healthy motor neurons receive excitatory signals from a glutaminergic neuron that 
releases glutamate, which binds to glutamate receptors. A motor neuron is also 
surrounded by microglia and astrocytes, which participate in the removal of glutamate 
from the synaptic cleft by transporting it though EAA2 transporter into their cell bodies. 
It has been observed in SOD1 mutant mouse model that the first event in the ALS 
development is in a muscle that loses the synaptic connection between the motor neuron 
and a muscle, seen as motor neuron retraction (Pun et al., 2006). This motor neuron 
terminal retraction in the early stage of the disease might be due to accumulation of 
SOD1 aggregates or neurofilament mis-accumulation, which affects the transport within 
the axon, and mitochondrial dysfunction derived from defective mitochondrial transport 
into and out of nerve endings.  
 
Activated microglia at the symptomatic stage of the disease, driven by SOD1 released 
from the motor neuron, produce toxic factors such as nitric oxide (NO) and tumor 
necrosis factor (TNF) alpha that target the same neuron. At the same time, high levels of 
glutamate in the synaptic cleft cause constant firing of the motor neuron and calcium 
entry trough AMPA receptors (Boillee et al., 2006). This glutamate driven toxicity has 
been a target of some drugs like riluzole. Toxic factors like nerve growth factor (NGF) 
are also released from the astrocytes, which at this point of a disease progress, lose the 
expression of glutamate transporter EAAT2. All of those events lead to caspase 
activation and motor neuron apoptosis and muscle atrophy at the end stage.  
 Motor neuron damage in ALS therefore appears to be caused not only 
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autonomously but also by neighboring cells. Microglia activation, and cd16 + monocytes 
increased in peripheral blood have been observed in both sporadic and familial ALS. The 
abnormally activated monocyte/macrophages correlated to the lipopolysaccharide (LPS) 
levels in the peripheral blood (Zhang et al., 2011). Also studies of SOD1 mutant mouse 
have shown that expressing SOD1mutation exclusively in the motor neuron and not in 
neighboring cells did not induce a disease in some mice.  
 
The fact that neuro-protection can be achieved by just targeting neighboring cells of a 
neuron has motivated trials for potential treatment options. Microglia treatment with 
minocycline inhibits their activation. TNFalpha antagonist injections or cyclooxygenase 2 
(COX2) inhibitor injections showed some promise when it comes to slowing disease 
onset (Zhu et al., 2002; Drachmanetal, 2002; West et al., 2004). Another nonneuronal 
neighbor target for the disease treatment is the astrocyte. Since expression of EAAT2 
glutamate transporter decreases during disease progression, beta-lactam antibiotics that 
act as transcriptional inducers of EAAT2 produce improved survival in transgenic SOD1 
mice (Rothstein et al., 2005). Also blocking release of glutamate could decrease injury, 
which appears to be a major action of riluzole. Although its mechanisms of action are not 
fully understood, they also include inactivation of voltage dependent sodium channels or 
prevention of glutamate binding to its receptors. In a study of SOD1 ALS mouse model, 
the drug extended their survival (Doble, 1996), and riluzole is currently the only FDA-
approved drug for ALS. 
Muscles as therapeutic targets in ALS 
 Muscles have been also used as therapy targets because muscles die without 
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neuronal stimulation. Increasing mass of muscle by decreasing expression of myostatin, 
which slows muscle development, didn’t improve ALS in SOD1 mutant mice (Holzbaur 
et al., 2006). Injecting insulin like growth factors IGF-1 caused revival of muscle fibers 
and life prolongation of SOD1 mice, therefore opened a possibility of growth factor 
therapies (Dobrowolny et al., 2005). Exercising, especially concomitant with IGF1, 
showed improvement in ALS transgenic mice (Kaspar et al., 2005).  
Growth factors show some benefit in ALS 
 Infusion of growth factor BDNF through into the brain by ICV or spinal cord 
intrathecal injection showed small benefits in patients (Nagano et al., 2005b). In mice 
VEGF encoding retrovirus delivery infusion to muscle or ICV injection of VEGF 
increased survival (Zheng et al., 2004). 
 
1.2 Mitochondrial genome 
Both genetic and sporadic forms of amyotrophic lateral sclerosis present clinically in very 
similar ways (Saris et al., 2009, Dupuis et al., 2011, Boillee et al., 2006). This relative 
homogeneity of the clinical phenotype of ALS led to a conclusion that there might be few 
pathways that are significant in the disease’s evolution. Since some of those pathways 
include signaling pathways in peripheral blood cells, it became evident that the peripheral 
blood could be used for the gene profiling and become a biomarker for diagnosis of ALS 
(Saris et al., 2009; Maes et al., 2007). Another study showed that throughout the course 
of ALS damage occurs not only to motor neurons but also to non-neural tissue, including 
peripheral lymphocytes (Curti et al., 1996). This damage affects bioenergetics of cells 
with mitochondria, being the energy factory, centrally involved in that damage (Dupuis et 
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al., 2011; Heath et al., 2013).  
Mitochondria were first described as “chlorophyll bodies” and “cell granules” at the end 
of the nineteenth century. Since then, mitochondria were more fully characterized in the 
1950’s. Lynn Margulis, who proposed the endosymbiotic theory, formulated their origins 
in the early 1970’s. According to this theory, oxidative proteobacteria were symbiotically 
incorporated into a prokaryotic or early eukaryotic cell and evolved to become modern 
mitochondria.  
 
The endosymbiotic theory is supported by molecular genetics and sequence homology 
comparisons between DNA of mitochondria and prokaryotes. The organelle’s ribosome’s 
are like prokaryotes (70S) and differ from cytoplasm of eukaryotes (80S). Other 
supportive arguments for the endosymbiotic theory include circular mitochondrion 
genome and its replication, initiation of RNA translation, and the double membrane of 
mitochondria (with the inner mitochondrial membrane being high in cardiolipin content, 
which is like bacterial membranes but different from eukaryotic plasma membranes). 
Mitochondria within the course of evolution adapted to being inside of the cell by 
transferring some of its genome into nucleus, reducing in this way their  “supplementary” 
genome and energy expenditures (Wallace, 1999).  
 
Mitochondria control many tasks in a cell. They include but are not limited to: initiation 
of cell death cascades, regulation of energy production, feedback regulation of Krebs 
cycle, maintaining calcium homeostasis, and formation of iron sulfur clusters. 
Deregulated of calcium homeostasis, as in the peripheral blood lymphocytes of ALS 
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patients, leads to uncoupling of oxidative phosphorylation (Curti et al., 1996). 
 
Figure 1.1. Many functions of mitochondrion. Reeve et al., 2012. 
 
Human mitochondrial genome consists of 16568 base pairs contained on heavy and light 
circular DNA strands. The lighter (based on G-C content), inner strand encodes ND6 and 
eight tRNA’s; the heavier outer strand encodes 12s and 16s rRNAs, 14 tRNAs, six 
subunits of complex I (ND1-5, ND4L), one subunit of complex III (cytochrome b), three 
subunits of complex IV (COX I-III), as well as two subunits of complex V (ATP 
synthase; ATP6, ATP8). These 13 genes encode proteins of the electron transport chain 
(ETC) that are necessary for the capturing of energy in the form of a proton gradient, and 
converting it to ATP in a process of oxidative phosphorylation (OXPHOS).  
 
The semiautonomous system of mitochondria relies also on the nuclear genome. The rest 
of the proteins, including 74 ETC proteins, enzymes, transcription factors, ribosomal 
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proteins, and polymerases are made outside of the mitochondria then imported and 
assembled there (Wallace, 1999; Bellance et al., 2009).  
 
Figure 1.2. Mitochondrial genome. Bellance et al., 2009. 
The D-loop is a regulatory, non-coding region, with promoters of heavy and light strands 
and the origin of replication Heavy strand (OH).  According to the ‘strand-asymmetric” 
explanation of mtDNA replication, the origin of replication of the light strand (OL) is 
located approximately 2/3 of the circumference from OH. The replication cycle is about 
two hours long and starts with the replication of the heavy chain proceeding 
counterclockwise.  
 
A single mitochondrial polycistronic mRNA encodes several different 
polypeptide chains (Bellance et al., 2009).  The mitochondrial genome is unique in many 
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aspects. It not only has a distinctive code for translating DNA and replicates 
independently from the nuclear genome, but also its RNA is capable of enzymatic 
activity and of joining two transcripts together with so-called trans-splicing  (Williams, 
2002). Human mitochondrial (mt) genome was thought to be mainly maternally inherited. 
This was attributed to the fact that paternal mitochondria present in the tail of sperm, do 
not enter an oocyte, and if they do, they are overcome by abundant maternal mtDNA and 
damaged by reactive oxygen species (ROS) (Luo et al., 2013; Williams, 2002). Despite 
this general belief, it has been observed in rare situations that mitochondria from the 
father can be passed to the offspring in humans. A patient of Schwartz and Vissing with 
trademarks of mitochondrial myopathy, ragged-red muscle fibers and exercise exertion, is 
one example of mitochondrial paternal inheritance. The detailed sequencing analysis of 
the mitochondrial genome in the quadriceps muscle of this patient has shown, that the 
mutation in the ND2 gene was derived from the father. Interestingly, the mutation was 
not present in circulating lymphocytes and that is consistent with the fact that 
mitochondrial mutations are often localized to a specific tissue (Schwartz and Vissing, 
2002; Williams, 2002). 
 
Mitochondrial DNA has a larger mutation rate than does nuclear DNA (Wallace, 1999). 
The mutation frequency increases with age even in a healthy person, and is accelerated in 
degenerative diseases (Williams, 2002). The mutated state (heteroplasmy) can be 
transferred to the somatic cell progeny and be a cause of diminishing bioenergetic 
capacity of a cell by a process known as “Muller’s ratchet” that describes increasing 
mutational burden associated with non-sexual reproduction of DNA. It follows that the 
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tissues affected the most by mitochondrial mutations, are the ones with high-energy 
demands like neurons, cardiac muscle and skeletal muscle. This energy and disease 
correlation was observed in many studies. For example, the mitochondrial DNA study by 
Keeney et al. showed increased mtDNA point mutations in spinal cord neurons of 
patients with ALS as well as decreased cytochrome oxidase activity, which is an 
important part of ETC. Also, a Parkinson's disease study showed increased abundances of 
mtDNA deletions that included cytochrome oxidase and complex I of ETC (Bender et al. 
2006).  
The cell energy production relies on the interaction of three processes that take place in 
mitochondria: oxidative phosphorylation, production of the radical oxygen species and 
apoptosis (Wallace, 1999). The interruption of this state of equilibrium by, for example, 
cellular mutations, leads to a disease. The energy currency of the cell, ATP is produced in 
mitochondrial ETC in the process of oxidative phosphorylation. The ETC consists of five 
complexes; NADH dehydrogenase (complex I; 7mt DNA {ND1-6, ND4L}, 40 nDNA), 
succinate dehydrogenase (complex II; 0mtDNA, 4nDNA), ubiquinol cytochrome C 
oxidoreductase (complex III; 1mtDNA{cytochrome b}, 10 nDNA), cytochrome C 
oxidase (complex IV; 3mt DNA {COX I-III}, 10 nDNA) and ATP synthase (complex V; 
2mt DNA {ATP6, ATP8}, 15 nDNA).  
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Figure 1.3. Inner membrane Electron Transport Chain of mitochondria. Bellance et al., 
2009. 
 
This chain of proteins oxidizes NADH and FADH2 that were produced in the Krebs 
cycle from the pyruvate from glycolysis. NADH and FADH2 enter the ETC at the 
complexes I and II respectively and electrons released in this process of oxidation are 
transferred to coenzyme Q. ComplexIII passes these electrons to cytochrome c, and 
cytochrome c to complex IV. Oxygen consumption takes place in complex IV where the 
O2 is “sucked up” by heme3 and reduced to H20. Complex V of ETC of mitochondria 
uses electrochemical proton gradient created by ETC (H+ moved to inter-membrane 
space) to generate ATP from ADP and phosphate. ETC although often described as 
consisting of single complexes is in reality an assembly of supercomplexes so called 
“respirasomes” that is few subunits of a specific complex bound to each other. The ratio 
of these complexes varies for different tissues. Respirasomes minimize diffusion 
distances of substrates and electron leakage (Schägger and Pfeiffer, 2001) and the 
leakage in ETC can cause oxidative damage to many cellular components including 
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cellular and mitochondrial membranes as well as it can inactivate the energy production 
through oxidative phosphorylation. 
 
Figure 1.4. Reactive Oxygen and Nitrogen Species. Bellance et al., 2009. 
 
Oxygen molecules that are abundant in mitochondrial matrix can accept free electrons 
that leave complex I and complex III of the ETC, yielding superoxide anion, that under 
normal conditions is converted to hydrogen peroxide by Mn/Mg superoxide dismutase 
(SOD-2). Mitochondria have high levels of reduced glutathione (GSH) that is a 
component of glutathione peroxidase and catalase can convert hydrogen peroxide to 
water. If that process of superoxide removal is deregulated it leads to generation of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) and causes oxidative 
and nitrosative damage of DNA, proteins and lipids.  
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Increased ROS can also cause opening of mitochondrial permeability transition 
pore (mtPTP), which leads to the initiation of apoptosis. The cascades of events follows; 
discharge of the electrochemical gradient of mitochondrial membrane, inflation of inner 
membrane, release of cytochrome c, activation of caspases and apoptosis. This interplay 
between oxidative phosphorylation, reactive oxygen species, apoptosis taking place in 
mitochondria is fundamental in bioenergetics of the cell. 
 
1.3 Induced Pluripotent Stem Cells (iPSCs) 
 
One of the main concerns of neurodegenerative studies is the amount of tissue available 
for research. Many studies utilize postmortem samples from autopsies (Payne et al., 
2014; Gage et al. 2013; Wang, 2006) with limited amount of nucleic acid for analysis 
from samples that are also at the final stage of the diseases. Also, the animal models 
created for studies are genetic, which do not necessarily reflect the most commonly 
occurring (~95%) sporadic forms of human ALS. This pursuit of plausible solutions to 
overcome these limitations has directed attention to induced pluripotent stems cells 
(iPSCs), induced neuronal phenotypes (iN), and somatic cell neural transfer (NT) 
(Wernig et al., 2013; Mertens et al. 2013; Staerk et al. 2010; Wang et al. 2013), and has 
inspired the development of disease models which could potentially lead to the advances 
in crucial treatment options for neurodegenerative diseases including ALS. The 
reprogrammed cells from genetically unique patients would allow studies of specific 
pathways in motor neurons even ahead of a disease manifestation, and would make for a 
plausible design of personalized pharmacological treatment (Gage et al., 2013). For 
therapy, iPSC’s could be differentiated to motor neurons, which can be delivered back to 
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the patient (Oakely et al., 2013). The reports of successful autologous transplantation of 
stem cells from bone marrow to ALS patients have been seen in studies (Feng et al., 
2012). 
 Among the somatic cell types that have been effectively reprogrammed into iPSC 
are mononuclear cells (MNC) (Dupuis et al., 2013). These blood cells, isolated from 
either the umbilical cord (CB) or adult peripheral blood (PMNC), offer several 
advantages among which is their low number of somatic mutations as a result of their 
short life span, compared to skin fibroblasts (Oakely et al., 2013; Feng et al., 2012) which 
are also used for iPSC generation. The other advantage is their short culture time as well 
as accessibility (Dupui et al., 2013). Originally human iPSC were derived using a 
retroviral vectors, however, the questionable safety of injecting a retro or lento-virus into 
humans and the resulting mutations they created (Yu et al., 2009) redirected attention of 
researchers to recombinant proteins usage. This approach, though plausible, was very 
inefficient (Dupuis et al., 2011) therefore a method of using non-integrating or excisable 
vectors and transduction of the reprogramming factors was developed (Dupuis et al., 
2013; Jaenish et al., 2013; Yu et al., 2009).  
 
The other experimental parameter that affects the quality of iPSC is the number of 
reprogramming factors and donor cells (Jaenish et al. 2013). Dupuis et al. reported a 
successful single plasmid transfection of pEB-C5 plasmid containing EBNA1/OriP OriP 
sequences of the Epstein-Barr with five reprogramming factors Oct4, Sox2, Klf4, c-Myc 
and Lin28. The plasmid was not integrated into the genome so it is much safer than using 
a retrovirus, and preferentially expanded erythroblasts over T lymphocytes before 
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reprogramming, since T lymphocytes have high number of somatic VDJ rearrangements 
(Dupuis et al., 2011; Yu et al., 2009). To improve reprogramming efficiency of PMNC 
sodium butyrate can be added to the media (Chou et al., 2011). 
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Chapter 2:  
 
2.1 Materials and Methods  
Tissue Culture 
Peripheral blood of two ALS and one non-ALS healthy control (CTL) patients was 
collected at the Parkinson’s and Movement Disorder’s Center Medical College of 
Virginia according to VCU IRB-approved protocol. Within four hours after blood 
collection, mononuclear cells (MNC) were separated from other blood cells using Ficoll- 
Paque Premium density-based centrifugation. In this method MNC, being of lower 
density, stay in the top layer above Ficoll which is a hydrophilic polysaccharide and the 
separation agent for this method.  QIAzol Lysis Reagent (Qiagen) was used to remove 
any remaining red blood cells. The peripheral blood MNC (PMNC) was stored at -80 
degrees Celsius. 
The generation of human induced pluripotent stem cells from PMNC was attempted by 
following the protocol of Dowey et al., 2012. 
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Figure 2.1. Generation of integration free human iPSC protocol. Dowey et al., 2012. 
 
MNC were isolated and expanded in MNC medium for 14 days. This medium was serum 
free with cytokines that would favor erythroblasts over lymphocytes development. On 
day 14 MNC were transfected with episomal plasmid pEB­ C5, expressing OriP 
sequences of the Epstein­Barr and five reprogramming transgenes Oct4, Sox2, Klf4, 
c-Myc and Lin28. The 4D-Nucleofector Core Unit and X Unit (Lonza) were used for 
reprogramming. This event started the generation of iPSCs. The cells were then 
transferred to feeder-coated plates containing mouse embryonic fibroblasts (MEF) and 
the medium was switched from MNC to MEF medium with antibiotic antimycotic and l-
glutamine. On the third day after transfection, MNC medium was replaced with 
embryonic stem cell (ESC) medium. The iPSCs colonies start multiplying on day 14. 
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Figure 2.2. An image of a commercial MNC (All Cells) that were transfected in previous 
experiments by another research group member. Image is of MNC two days after 
transfection stained with a GFP green fluorescent protein (GFP) plasmid.  It was a 
positive control for the transfection process.  
 
 
. 
Figure 2.3. An image of a commercial MNC (All Cells) that were transfected in previous 
experiments by another research group member. Image is of MNC two days after 
transfection stained with just PBS as a negative control. 
 
Two weeks after the transfection, cells can be stained with TRA-1-60 antibody to confirm 
the identity of successfully reprogrammed iPSCs colonies. Unfortunately, in my 
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experiment after morphological assessment of the cell culture, no iPSC were identified, 
therefore TRA-1-60 staining was not performed.   
 
Figure 2.4. An image of a commercial MNC (All Cells) that were transfected in previous 
experiments by another research group member. Image is of the same MNC cell line as in 
Figure 2.2 and Figure 2.3 fourteen days after transfection with plasmids.  It has been 
stained with an antibody to TRA-1-60, which is an early marker of pluripotency.  
 
RNA and DNA extractions 
The extraction process is used to separate DNA and RNA from biological samples using 
chemical and physical methods. The intricacy of the RNA extraction lies in the 
realization of omnipresence of RNAases that degrade RNA and making a great effort to 
eliminate them.  
In this experiment RNA and DNA were extracted from PBMC samples using an AllPrep 
DNA/RNA Mini Kit (Qiagen), which allowed simultaneous purification of genomic 
DNA and total RNA. The first step of DNA/RNA extraction was disruption of plasma 
membrane using RLT buffer containing guanidine thiocyanate followed by samples’ 
homogenization to reduce the viscosity of the lysate. This would allow for better binding 
of DNA and RNA to mini spin columns. The DNA was separated from RNA using 
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AllPrepDNA mini spin column to which DNA bound. Consequently, ethanol was added 
to the eluted RNA to precipitate it. The next steps for RNA and DNA extraction consisted 
of adding RW1 buffer with ethanol to the RNA column and AW1 buffer with 
Guanidinium hydrochloride to DNA column, then washing them.   
 
Following the DNA and RNA extraction, both nucleic acids were subjected to quality 
control (QC) using Nanodrop 2000c spectrophotometer (Thermo Scientific) for DNA and 
Experion Automated Electrophoresis System (Bio-Rad) for RNA.  
Experion RNA StdSens analysis kit was used to determine total RNA concentration and 
establish its integrity using RNA quality indicator (RQI) number with a scale 1-10, 10 
being the highest. After the chip preparation, which included adding gel stain containing 
fluorescent dye and sieving matrix, the chip was inserted into the electrophoresis station 
with voltage sensitive electrodes. Charged RNA fragments were separated on their size 
basis (virtual gel matrix), and the fluorescent dye penetrated the fragments. Following the 
detection by a photodiode of fluorescence of the laser-exciting sample fragments, the 
software created fluorescence intensity versus time plots (electropherogram). The total 
RNA sample was separated into two peaks that represented 18S and 28S ribosomal RNA 
(rRNA) and the software compared the area under the electropherogram to calculate total 
concentration of the sample. RNA was then reversely transcribed to cDNA using iScript 
(Bio-Rad) using GeneAmp PCR system 9700 (Applied Biosystems). 
 
Nanodrop 2000c spectrophotometer (Thermo Scientific) was used for quality control 
(QC) of DNA, which measured the intensity of light transmitted through the sample. The 
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absorbance at a given wavelength was then calculated according to the equation:  
 
Absorbance= -log [Intensity of sample/Intensity of blank] 
 
The Beer-Lambert equation was used to correlate the calculated absorbance with 
concentration:  
A = ε * b * c 
 
Where A is the absorbance represented in absorbance units (A), ε is the extinction 
coefficient liter/mol*cm, b is the length of solution the light passes through in cm, and c 
is the analyte concentration in moles/liter or molarity (M). 
The reference buffer used in this experiment was Tris (hydroxymethyl) aminomethane - 
Ethylenediaminetetraacetic acid (Tris- EDTA that is TE) buffer in which DNA was 
dissolved. TE solubilizes DNA while protecting it from degradation. To assess the purity 
of DNA the ratio of absorbances at 260nm/280nm was calculated. DNA absorbs UV light 
at 260 and 280 nanometers and pure DNA has a ratio of 1.8.  A lower ratio may indicate 
presence of protein, phenol or other contaminants because aromatic proteins absorb UV 
light at 280 nm. The secondary measurement of 260nm/230nm additionally assesses 
nucleic acid purity. A ratio of 260/230 lower than 1.8-2.2 indicates the presence of 
copurified contaminants. 
 
Selection of Genes of interests and Quantitative PCR  
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Real time polymerase chain reaction (qPCR) is a technique that amplifies and 
simultaneously quantifies a targeted molecule utilizing the physiochemical properties of 
nucleic acids and DNA polymerase. It provides an amplification plot based on the 
changes in fluorescence, which is proportional to the amount of the target. QPCR is also 
a common technique for studying gene expression of neurological diseases. The 
advantage of this method is the sensitivity of the measurement to small amounts of 
mRNA. However, this technique entails the necessity of normalization to housekeeping 
genes that are transcribed continuously at a constant rate, which guarantees a stable level 
of mRNA regardless of the experimental condition. Geometric means need to be used 
because the absolute expression levels of reference genes can vary widely, and geometric 
means (as opposed to typical arithmetic means) distribute this difference. GeNorm is 
used to find the least variable reference genes in the cells of interest, independently of 
their absolute expression levels. Also, cell types and disease progression, and their 
amount, would be comparable to the analyzed genes. According to Penna et al. (2011) 
and their GeNorm and NormFinder analysis of gene stability, the most stable reference 
gene in postmortem brain was CYC1, however; they recommended a combination of 
reference genes. Following the experience from our research group (Keeney et. al., 2010) 
the housekeeping genes chosen for normalization were TOP1 (encodes DNA 
topoisomerase type I which enzymatically breaks and rejoins a single strand of DNA), 
GAPDH (encodes glyceraldehyde-3-phosphate dehydrogenase, an enzyme that catalyzes 
the sixth step of glycolysis, which has been extensively used in different studies as a 
reference gene (Penna et al. 2011), YWHAH (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, which encodes a 14-3-3  family of proteins that 
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mediate signal transduction in cells by binding to phosphoserine containing proteins) and 
CYC1 (encodes cytochrome C1, mitochondrial heme protein). The normalization factor 
for mtDNA was a geometric mean of GAPDH and YWHAH for mtDNA and TOP1 and 
CYC1 for mt cDNA. 1  
It was crucial to establish suitable candidates for the gene analysis. According to Keeney 
et al. (2011), the mitochondrial genes encoding respiratory proteins ND4 and COX III are 
frequently deleted in cervical spinal cord major arc ALS patients and ND2 is also deleted 
but less frequently. The 12s rRNA gene product is involved in the assembly of proteins 
within cells present only in mitochondria. 
QPCR was performed with human mtDNA copy number standards (for mtDNA qPCR) 
or human fetal brain cDNA (for mt cDNA qPCR) using iQ Multiplex Power Mix in a 
CFX-96 Real-Time PCR instrument iCycler with aniQ5 detection system (BioRad, 
Hercules, CA). MtDNA genes ND2, ND4, COX III, and 12s rRNA were measured using 
dyes (FAM- ND2, Texas Red- ND4, TET- COX III, Quasar- 12s rRNA) as well as sense 
and antisense primers. Each sample and standard was quadrupled. The cycling protocol 
consisted of activation at 95°C for 5 min followed by 50 cycles of: 95°C melting for 10 
seconds  (allowing for the separation of the double chain), and 50°C for 1 minute 
(allowing for the binding of the primers with the DNA template). Data was analyzed 
using the iQ5 software. QPCRs for the reference genes GAPDH, YWHAH, TOP1, CYC1 
were performed individually using EvaGreen® Supermix (BioRad) and primers designed 
for PCR. The standard curves generated showed similar efficiencies of the qPCR runs. 
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2.2 Results   
Tissue culture 
In this study another research group member cultured MNC from ALS patients. I cultured 
MNC from a CTL subject. My two additional MNC cultures from ALS patients were 
contaminated during the course of the study, and the efforts of reprogramming MNC to 
iPSCs from the CTL subjects were unsuccessful for the reasons addressed in discussion. 
After morphological assessment of my cell culture, no iPSC were identified; therefore 
TRA-1-60 staining was not performed. 
 
RNA and DNA Quality Control 
For ALS and control PBMC samples the quality indicator (RQI) numbers were between 
9.8 -10. For the CTL sample before culturing, however (sample number 9), there was a 
critical anomaly error, which could have been due to some contamination. It could not 
have been a result of RNA concentration, which was not the lowest one (62 ng/ul). The 
RNA concentrations ranged between 38.25 ng/ul for the ALS sample I before culturing, 
and 257.39 ng/ul for the ALS sample II after culturing (See Table 2.1).  
 
W ell ID Samp le Na me RNA  Area R NA  Conc ent ra tion (ng/!l) Rat io [ 28S /1 8S] RQ I RQ I C lass ificat ion RQ I Alert
L La dd er 83 6 .1 4 160
1 AL S4 6 I 19 9 .8 9 38. 25 0. 02 1 0 G reen
2 ALS  46 # 1 8 62. 8 165. 1 1. 88 9. 8 G reen
3 A LS 4 6# 2 77 4 .7 7 148. 26 1. 73 9. 9 G reen
4 A LS 4 6# 3 83 1 .1 4 159. 04 1. 96 1 0 G reen
5 A LS  4 8 II 21 7 .8 7 41. 69 2. 05 1 0 G reen
6 A LS 4 8# 1 80 1 .0 3 153. 28 1. 64 9 G reen
7 A LS 4 8# 2 68 7 .3 2 131. 52 2. 07 1 0 G reen
8 A LS 4 8# 3 13 45. 07 257. 39 1. 85 9. 9 G reen
9 CTL  4 7 I 32 4 .1 2 62. 02 2. 25 N/ A Critical A nom aly
1 0 C TL  47# 1 30 3 .0 5 57. 99 0. 06 1 0 G reen  
Table 2.1. Quality Control results of RNA using Experion Automated Electrophoresis 
System (Bio-Rad). 
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The measured 260/280 ratios for the DNA samples were within 1.86-1.89 range, which 
confirmed their purity from aromatic proteins. However, there might have been some 
other contaminant in the CTL sample before culturing (sample number 9), because the 
ratio 260/230 was much lower than the purity range that is 0.63. 
The DNA concentrations varied between 128.5 ng/ul for the sample 10 (CLT after 
culturing) and 311.4 ng/ul for the sample 8 (ALS 48 after culturing) (See Table 2.2) 
 
# S a m pl e  ID Us e r  na me Da t e  a n d Ti m e Nuc le i c Aci d  Co nc. Uni t A260 A280 260 /2 80 26 0/ 230 Sa m p l e  Ty pe Fa ctor
1 1  AL S 4 6 I Adm inist rat or 5 / 21 /2 014 11: 35: 56 A M 270 ng/!l 5 .4 2.9 1. 86 2. 03 DNA 50
2 2  AL S 4 6 #1 Adm inist rat or 5 / 21 /2 014 11: 37: 36 A M 250 ng/!l 5 2 .67 4 1. 87 2. 08 DNA 50
3 3  AL S 4 6 #2 Adm inist rat or 5 / 21 /2 014 11: 38: 34 A M 231. 4 ng/!l 4. 627 2 .45 3 1. 89 1. 83 DNA 50
4 4  AL S 4 6 #3 Adm inist rat or 5 / 21 /2 014 11: 39: 36 A M 223. 5 ng/!l 4. 471 2 .38 5 1. 87 2. 04 DNA 50
5 5  AL S 4 8 I Adm inist rat or 5 / 21 /2 014 11: 40: 39 A M 197. 8 ng/!l 3. 955 2 .12 1 1. 86 1. 4 DNA 50
6 6  AL S 4 8 #1 Adm inist rat or 5 / 21 /2 014 11: 41: 45 A M 295 ng/!l 5. 899 3 .15 5 1. 87 2. 09 DNA 50
7 7  AL S 4 8 #2 Adm inist rat or 5 / 21 /2 014 11: 42: 36 A M 254. 9 ng/!l 5. 098 2. 73 1. 87 1. 84 DNA 50
8 8  AL S 4 8 #3 Adm inist rat or 5 / 21 /2 014 11: 43: 37 A M 311. 4 ng/!l 6. 228 3 .32 5 1. 87 1. 96 DNA 50
9 9  C TL  4 7 III Adm inist rat or 5 / 21 /2 014 11: 44: 45 A M 242. 5 ng/!l 4. 85 2 .60 1 1. 86 0. 63 DNA 50
1 0 10  C TL  4 7 #1 Adm inist rat or 5 / 21 /2 014 11: 46: 01 A M 128. 5 ng/!l 2. 57 1 .38 5 1. 86 1. 54 DNA 50
 
Table 2.2. Quality Control results of DNA using Nanodrop 2000c spectrophotometer 
(Thermo Scientific).  
 
 
Mitochondrial cDNA/ RNA quantification 
The results of qPCR were normalized to two housekeeping genes CYC1 and TOP1 by 
dividing SQ means by the geometric mean of two housekeeping genes. Mt cDNA of 
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analyzed genes ND2, ND4, COX III and 12s rRNA showed higher gene expression in 
ALS MNC before culturing compared to CTL before culturing for all genes. 
Specifically, ND2 expression was increased by 2.4 for ALS comparing to CTL which 
was increased by 1.6 and COX III expression increased by 2.6 for ALS versus CTL 
increase of 2. There was no apparent increase of gene expression for 125s rRNA (1.1 for 
ALS and 0.8 for CTL) and ND4 (1.05 for ALS .95 for CTL)(Figures 2.5-2.8). 
 
Figure 2.5. ND2 gene expression in ALS versus CTL MNC before and after culturing.  
 
 
Figure 2.6. COX III gene expression in ALS versus CTL MNC before and after 
culturing. 
 
  
Figure 2.7. 12s rRNA gene expression in ALS versus CTL MNC before and after 
culturing. 
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Figure 2.8. ND4 gene expression in ALS versus CTL MNC before and after culturing. 
 
After culturing, ALS and CTL gene expression was decreased for all genes in comparison 
to ALS and CTL gene expression before culturing. ALS gene expression was comparable 
to CTL gene expression for all genes. 
 
mtDNA copy numbers 
The results of qPCR were normalized to two housekeeping genes GAPDH and YAHWZ 
by dividing SQ means by the geometric mean of two housekeeping genes. Mitochondrial 
DNA copy numbers of analyzed genes ND2, ND4, COXIII and 12s rRNA were increased 
in MNC after culturing compared to copy numbers before culturing for all ALS and CTL 
samples. There was an increase in copy numbers for the respiratory genes ND2, ND4, 
COX III which was ~1200000 for ALS compared to ~1000000 copy numbers of CTL. 
There was no apparent difference in copy numbers of 12s rRNA expression of ALS 
compared to CTL. Copy numbers for CTL were higher for all genes after culturing 
comparing to before culturing (Figures 2.9 – 2.12). 
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Figure 2.9. ND2 mtDNA copy numbers in ALS versus CTL MNC before and after 
culturing. 
 
 
 
Figure 2.10. COX III mtDNA copy numbers in ALS versus CTL MNC before and after 
culturing. 
 
 
  
Figure 2.11. 12s rRNA mtDNA copy numbers in ALS versus CTL MNC before and after 
culturing. 
 
 
ND2 copy Numbers. Normalized 
COXIII copy Numbers. Normalized 
12s rRNA copy Numbers. Normalized 
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Figure 2.12. ND4 mtDNA copy numbers in ALS versus CTL MNC before and after 
culturing. 
 
 
 
 
 
 
2.3 Discussion 
 
ALS, despite tremendous research efforts and palliative therapy advances, remains a 
lethal motor neuron disease. The etiology of ALS, most of which occurs sporadically, is 
still unknown and the endeavor dedicated to its characterization and finding consequent 
treatment options, led scientists to intensive research of cell components. Given the 
heterogeneity of sporadic ALS clinically, there may be different etiologies and 
mechanisms responsible for progression. Free radicals’ formation, oxidative stress, 
autophagy, and mitochondrial dysfunction lead to energy deficiencies of cells in animal 
models (Dupuis et al., 2011; Wallace et al. 1999., Curti et al., 1996; Oakley et al. 2013). 
Each of these processes, singly or in combination, may underlie the origin(s) and 
progression of ALS. 
Extensive studies have tried to find genes responsible for ALS. In this search, few 
nuclear genes have been identified that are linked to the disease. Mutation in SOD1 gene 
ND4copy Numbers. Normalized 
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resulting in toxic aggregates causes not only impairment for proteasomes and cellular 
chaperones but SOD1 transport and accumulation in mitochondria may play a negative 
affect on calcium channels, electron transport chain and may prematurely trigger 
apoptosis. Other cellular aggregates like 43-kDa (TDP-43), fused sarcoma protein (FUS) 
and neurofilaments have been also observed as characteristic of a disease progression 
(Kwiatkowski et al., 2009; Dupuis et al., 2011; Garcia et al., 2006). Not only the motor 
neuron itself but also its neighbors are central players in ALS.  
Microglia and astrocytes can also release toxic factors that contribute to the 
disease development. Activation of microglia leads to release of glutamate that resides 
longer in the synaptic cleft because it can not be removed by glutamate transporters 
(which are lost from astrocytes during ALS progression). This leads to perpetual 
activation of the motor neuron and calcium influx. 2 
It has been observed that ALS not only affects the nervous system but also has a 
holistic impact on the body and all its cells. In particular, peripheral mononuclear cells 
may be taken into consideration as potential screening candidates for detecting the 
disease at early stages (Zhang et al., 2011). Looking at bioenergetic deficiency of a cell 
and mitochondrial gene expression could lead to ALS characterization at different stages 
of its progress. Also peripheral blood MNC can be used to develop induced pluripotent 
stem cells (iPSC) leading to potential treatment options of ALS and many other 
degenerative diseases, such as Parkinson’s and Alzheimer’s disease. 
In this work we tried to induce PSC from mononuclear cells taken from the 
peripheral blood of patients with ALS and healthy control. The protocol for MNC 
expansion was used according to Dowey et al., 2012. According to this protocol MNC 
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were isolated and expanded in serum free MNC medium with cytokines for 14 days. On 
day 14 MNC were transfected with episomal plasmid containing reprogramming 
transgenes Oct4, Sox2, Klf4, c-Myc and Lin28, which started the generation of iPSCs. 
Consequently, transfected MNC expanded in different media favoring development of 
iPSC. 
 Starting with three samples, peripheral MNC from two ALS patients and one 
control CTL, the two ALS samples have been contaminated during the course of MNC 
expansion. Working with a tissue culture demands a sterile technique. This technique 
involves special training and different cells have different susceptibility to contamination. 
I received training on SY5Y cells, which is human neuroblastoma cell line. Working with 
human MNC samples requires more precise and finer technique comparing to SY5Y 
because of the amounts of cells and media contained in wells comparing to flasks of 
SY5Y cells. The factors mentioned above plus multiple steps, elaborate, every day 
preparation of different media for MNC expansion may have contributed to the 
contamination of cells. The SY5Y cell line had only one type of media prepared in 
advance limiting the possibility of contamination. In the course of learning the sterile 
technique, the CTL cell line was not contaminated. Despite the efforts of expansion and 
the cell culture, I did not detect any iPSCs.  The unsuccessful reprogramming of MNC to 
iPSCs could be attributed to many factors. Peripheral blood monocytes have lower 
reprogramming efficiency than cord blood (Chou et al., 2011). The cell counts of my 
original CTL sample were low at the beginning of the expansion, and the colony was 
growing poorly, which might be an indicator of sample contamination, especially after 
considering the quality control index CQ of RNA and DNA for that sample. Additionally, 
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nucleofection, which transfers substrates (in this case plasmid) into the cell by applying 
an external electric field, causes excessive cell death and can be responsible for low 
transfection efficiency. Many of the cells die at this point before colonies can develop.  
 
For future studies to enhance reprogramming efficiency, the starting MNC cell count 
should be chosen to be higher as compared to Dowey et al. Few adjustments could have 
been made to my experiment to obtain better results. Being able to ensure the quality of 
the blood samples before the cell expansion could have been an advantage since the 
growth of the colonies and quality of DNA and RNA might have been affected by the 
quality of blood MNC before culturing. No staining experiment was performed to 
exclude possibility of omitting the iPSC colonies during the transfer to different media. 
There was also no absolute identification of the colonies after iPSC expansion only the 
morphological assessment. After the transfection the colonies were picked manually 
under the microscope, which could have contributed to the excluding iPSC cell lines. The 
iPSC colonies might have been lost during the course of expansion because some of them 
did not adhere to the gel. 
 
 
The significant drawback of my study was the limited sample numbers. Working with 
more samples could be very beneficial, as it would identify the outliers and minimize the 
experimental error. Also, having just one control sample with lower quality of DNA 
could have misled the conclusions.  
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The qPCR mitochondrial gene expression study showed that mitochondrial cDNA 
of analyzed genes ND2, ND4, COX III and 12s rRNA was higher in ALS MNC before 
culturing compared to CTL before culturing for all genes. This increase in cDNA might 
be an indicator of increased protein numbers in ALS patients as a response to higher 
energy demands. An increase was observed in mitochondrial DNA copy numbers of 
analyzed genes ND2, ND4, COX III and 12s rRNA in MNC after culturing compared to 
copy numbers before culturing for all ALS and CTL samples. This is opposite to what 
occurred in the cDNA samples. There was a decrease in cDNA gene expression for both 
ALS and CTL after culturing. Therefore mtDNA copy numbers in genomic DNA 
increased slightly after culturing, but cDNA consistently decreased after culturing. This 
discrepancy between mtDNA copy number and mtRNA (as cDNA) expression might be 
contributed to the fact that we did not determine appropriate reference genes for the MNC 
after culturing which is a shortcoming of this study. GeNorm analysis would be necessary 
because monocytes after culturing are in principle different cells then before culturing.  
Looking at the graphs, the proportional decrease in gene expression after culturing 
appears greater in ALS compared to CTL, whereas mtDNA gene copy numbers increase 
more in CTL than in ALS. Therefore ALS samples appear more impaired than CTL in 
increasing their mtDNA copy numbers and lose more mtDNA gene expression. 
 
There was no apparent difference in copy numbers of 12s rRNA genes of ALS 
compared to CTL which could be attributed to the fact that 12s rRNA has a separate 
transcriptional promoter from the genes encoding respiratory proteins ND2, ND4, and 
COX III which is not affected in the course of ALS. Only COXIII and ND4 had 
increased expression in ALS patients in comparison to CTL. Although mtDNA copy 
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numbers were not markedly reduced in ALS MNC blood compared to CTL MNC, it 
supports results of Keeney et al. where mtDNA gene copy numbers in ALS spinal motor 
neurons decreased in ALS patients. Overall, these results implicate deregulated 
mitochondrial bioenergetics at a systems level as a characteristic of ALS. 
For future experiments it would be beneficial to see and compare the 
demographics of patients with ALS to draw accurate conclusions and make connections 
between age, sex and familial history of ALS. It would be also valuable to carry out a 
study on patients’ family members, and compare their mitochondrial gene expression. 
Periodical screening of MNC mitochondrial gene expression of the same patient would 
contribute to understanding of the processes that guide ALS progression and would 
reveal its correlations to mitochondrial bioenergetics. If that is successful then peripheral 
mononuclear cells may be considered as potential screening candidates for detecting the 
disease at early stages. It would be also beneficial to look at potential cross talk between 
the MNC and other blood components by testing for inflammatory cytokines, growth 
factors and necrosis factors, which could also change during the disease’s course and 
could be indicators of disease progression and could aid ALS diagnosis. 
 
2.4 Conclusion 
 
The motivation for this thesis has been an examination of was to examine the 
mitochondrial genome in the mononuclear cells of amyotrophic lateral sclerosis (ALS) 
patients. The deviations in the gene expression could contribute to the mitochondrial 
energy deficiency and be an underlying cause of this lethal neurological disorder of 
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motor neurons. The mitochondrial DNA genes examined were ND2, ND4, COXIII and 
12s rRNA. The qPCR mitochondrial gene expression study showed that mitochondrial 
DNA copy numbers in genomic DNA increased slightly after culturing, but cDNA 
consistently decreased after culturing. The results implicate deregulated mitochondrial 
bioenergetics as a characteristic of ALS. Future studies with reevaluated choice of 
housekeeping genes and potential temporal study of mitochondrial genome could lead to 
future elucidating the origins of ALS. The development of a disease model from induced 
pluripotent stems cells (iPSCs) have been explored as a potential treatment option for 
neurodegenerative diseases including amyotrophic lateral sclerosis. The reprogramming 
of mononuclear cells (MNC) to iPSCs would allow for a plausible design of personalized 
pharmacological treatment, as iPSCs differentiated to motor neurons, which could be 
delivered to the same patient and uniquely target the disease. The technique of 
transfection of mononuclear cells with non-integrating episomal plasmid has a great 
potential for successful reprogramming of mononuclear cells into iPSC however for 
future studies it can be improved by increasing the number of MNC before nucleofection.
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